Business
Healthcare Industry Veteran, Thomas Tulip, Joins FluoroPharma Medical, Inc.
Healthcare Industry Veteran, Thomas Tulip, Joins FluoroPharma Medical, Inc..
About this update from Fluoropharma Medical Inc
[{"type":"text","content":"\nHealthcare Industry Veteran, Thomas Tulip, Joins FluoroPharma Medical, Inc. \n\nHealthcare Industry Veteran, Thomas Tulip, Joins FluoroPharma Medical, Inc.\n\n\nBroad Healthcare Industry and Global Experience Will Advance FluoroPharma's Nuclear Cardiology Strategy \n\nMONTCLAIR, NJ--(Marketwired - October 06, 2015) - FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, announced today that Dr. Thomas H. Tulip will join the company as President and will be responsible for the Company's day-to-day operations, with a focus on global product and business development strategies.\"We are delighted that Thom Tulip, a distinguished healthcare veteran with vast experience in pharmaceutical development across the health care continuum, from pre-clinical discovery to commercialization of diagnostics, has joined our company at such a defining moment in our evolution. Today's announcement reflects the confidence we have in our vision to enable personalized medicine through precision diagnostics, the strength of our science and the promise of our portfolio,\" said Thijs Spoor, Chairman and CEO of FluoroPharma.Prior to joining FluoroPharma, Dr. Tulip served in leadership roles at Navidea BioPharmaceuticals, Inc. from 2011-2015. He spent more than 25 years in the development and commercialization of radiopharmaceuticals and imaging agents, with a track record of success in R&D, business development, brand and alliance management as well as international business. Prior to his tenure at Navidea Biopharmaceuticals, Dr. Tulip held senior leadership positions at Alseres Pharmaceuticals, Lantheus Medical Imaging (LMI), Bristol Myers Squibb (BMS) and DuPont, where his roles spanned product discovery and development, business and technology planning, brand and alliance management and international business management. He served as President of Alseres Molecular Imaging where he led efforts to develop markets for a Phase III neuroimaging agent. While at BMS and DuPont , he was instrumental in the development, commercialization and international management of the highly successful nuclear cardiology franchise, successfully built the BMS Medical Imag...